Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05202301 · ClinicalTrials.gov registry record
A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely
A clinical trial of Prostate Cancer, sponsored by Bayer.
- Completed
- Registry status
- 13,779
- Enrollment target
- 1
- Study location
NCT05202301 is a study of Prostate Cancer that has completed, run by Bayer. The registered enrollment target is 13,779 participants, above the 590-participant average among 735 other Prostate Cancer trials with a reported enrollment target (2235% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05202301, a study of Prostate Cancer, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 13,779 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an observational study in which patient data from the past on men with prostate cancer are studied. Cancer is a condition in which the body cannot control the growth of cells and tumors may form. If tumors form in the prostate, male sex hormones (androgens) can sometimes help the cancer spread and grow. Cancer that spreads to other parts of the body is called metastasis. Androgens are mainly made in the testicles. There are treatments available for men with prostate cancer to lower the levels of these hormones in the body. These treatments are called androgen deprivation therapy (ADT). Some men with prostate cancer respond to ADT, but in some cases, prostate cancer may overcome the therapy and worsen despite low androgens levels. Second generation androgen receptor inhibitors (SGARIs) including darolutamide, apalutamide, and enzalutamide are available for the treatment of prostate cancer in addition to ADT. SGARIs work by blocking androgens from attaching to proteins in cancer cells in the prostate. Clinical studies have shown that men with prostate cancer benefit from these treatments. But besides benefits, unfavorable reactions related to these treatments also influence which treatment is chosen, if the treatment is taken as intended or if it is even stopped. Unfavorable reactions observed for darolutamide, apalutamide, and enzalutamide differ from each other. In clinical trials, severe unfavorable reactions occurred less often for darolutamide. But information on how unfavorable reactions of each treatment influence their intake in actual or "real-world" prostate cancer treatment is missing. The main aim of this observational study is to learn to what extent SGARI treatments are taken as prescribed and how often their intake is completely stopped. To find this out, researchers will collect available treatment data of adult men with prostate cancer from the United States who started SGARI treatments between August 2019 and March 2021. The data will
Conditions Studied
Interventions
- DRUG Apalutamide
- DRUG Enzalutamide
- DRUG Darolutamide (Nubeqa, BAY1841788)
Study Locations (1)
New Jersey
- Bayer - Whippany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13,779 participants |
| Start Date | 2022-01-15 |
| Est. Completion | 2025-07-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05202301
The ClinicalTrials.gov registry entry for NCT05202301 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 13,779 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 590-participant average among 735 other Prostate Cancer trials with a reported enrollment target (2235% higher). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Apalutamide is the first listed.
NCT05202301 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT05202301 about?
NCT05202301 is a clinical study titled "A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely". This is an observational study in which patient data from the past on men with prostate cancer are studied. Cancer is a condition in which the body cannot control the growth of cells and tumors may form. If tumors form in the prostate, male sex hormones (androgens) can sometimes help the cancer spr...
What is the current status of trial NCT05202301?
This trial is currently completed. The enrollment target is 13,779 participants. The study started on 2022-01-15. Estimated completion is 2025-07-15.
What conditions does trial NCT05202301 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT05202301?
The interventions under investigation include: Apalutamide (DRUG), Enzalutamide (DRUG), Darolutamide (Nubeqa, BAY1841788) (DRUG).
Who is sponsoring clinical trial NCT05202301?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05202301 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.